Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Completed 6Unknown 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Colorectal Neoplasms 4Rectal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Colonic Neoplasms 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Has results × Trifluridine × Clear all
NCT04109924 2026-02-10

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study

Roswell Park Cancer Institute

Phase 2 Completed
42 enrolled 12 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Merck Sharp & Dohme LLC

Phase 3 Completed
563 enrolled 32 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Completed
102 enrolled 11 charts
Gastrointestinal

Colorectal Neoplasms

NCT02743221 2024-08-20

TASCO1

Servier

Phase 2 Completed
154 enrolled 15 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed
20 enrolled 9 charts
Gastrointestinal

Gastric Adenocarcinoma

NCT04072445 2023-08-09

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Mayo Clinic

Phase 2 Completed
28 enrolled 20 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡